A novel mouse model of familial combined hyperlipidemia and atherosclerosis
In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg-1·d-1) and fenofibrate (100 mg·kg-1·d-1). HCD-treated hApoC3-Tg mice demonstrated elevated levels of serum TG, total cholesterol (TC) and low density lipoprotein-cho...
Source: Acta Pharmacologica Sinica - March 8, 2024 Category: Drugs & Pharmacology Authors: Mei-Jie Chen Yi-Tong Xu Lu Sun Zhi-Hua Wang Peter J Little Li Wang Xun-de Xian Jian-Ping Weng Suo-Wen Xu Source Type: research
A novel mouse model of familial combined hyperlipidemia and atherosclerosis
In this study, we constructed a novel mouse model of familial combined hyperlipidemia through inserting a human ApoC3 transgene (hApoC3-Tg) into C57BL/6 J mice and injecting a gain-of-function variant of adeno-associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9)-D377Y concurrently with high cholesterol diet (HCD) feeding for 16 weeks. In the last 10 weeks, hApoC3-Tg mice were orally treated with a combination of atorvastatin (10 mg·kg-1·d-1) and fenofibrate (100 mg·kg-1·d-1). HCD-treated hApoC3-Tg mice demonstrated elevated levels of serum TG, total cholesterol (TC) and low density lipoprotein-cho...
Source: Acta Pharmacologica Sinica - March 8, 2024 Category: Drugs & Pharmacology Authors: Mei-Jie Chen Yi-Tong Xu Lu Sun Zhi-Hua Wang Peter J Little Li Wang Xun-de Xian Jian-Ping Weng Suo-Wen Xu Source Type: research
Andrographolide Improves ApoE4-Mediated Blood –Brain Barrier Injury by Alleviating Inflammation
In conclusion, Andro is a potent natural product which can protect the blood–brain barrier. (Source: Molecular Neurobiology)
Source: Molecular Neurobiology - March 6, 2024 Category: Neurology Source Type: research
ZeXieYin formula alleviates atherosclerosis by inhibiting the MAPK/NF-kappaB signaling pathway in APOE-/- mice to attenuate vascular inflammation and increase plaque stability
CONCLUSION: Our results suggested that ZXYF could reduce inflammation and increase plaque stability by inhibiting the MAPK/NF-κB signaling pathway, which provided a theoretical basis for clinical application and subsequent research.PMID:38437888 | DOI:10.1016/j.jep.2024.117969 (Source: Atherosclerosis)
Source: Atherosclerosis - March 4, 2024 Category: Cardiology Authors: Rumin Huang Yan Sun Ruiyi Liu Boran Zhu Hailou Zhang Haoxin Wu Source Type: research
Atorvastatin
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Pathogenic mycobacterium upregulates cholesterol 25-hydroxylase to promote granuloma development via foam cell formation
iScience. 2024 Feb 12;27(3):109204. doi: 10.1016/j.isci.2024.109204. eCollection 2024 Mar 15.ABSTRACTPathogenic mycobacteria orchestrate the complex cell populations known as granuloma that is the hallmark of tuberculosis. Foam cells, a lipid-rich cell-type, are considered critical for granuloma formation; however, the causative factor in foam cell formation remains unclear. Atherosclerosis is a chronic inflammatory disease characterized by the abundant accumulation of lipid-laden-macrophage-derived foam cells during which cholesterol 25-hydroxylase (CH25H) is crucial in foam cell formation. Here, we show that M. marinum (...
Source: Atherosclerosis - February 29, 2024 Category: Cardiology Authors: Shuang Zhou Ding Zhang Dan Li Hankun Wang Cairong Ding Jingrui Song Weifeng Huang Xuan Xia Ziwei Zhou Shanshan Han Zhu Jin Bo Yan Jacqueline Gonzales Laura E Via Lu Zhang Decheng Wang Source Type: research
Pathogenic mycobacterium upregulates cholesterol 25-hydroxylase to promote granuloma development via foam cell formation
iScience. 2024 Feb 12;27(3):109204. doi: 10.1016/j.isci.2024.109204. eCollection 2024 Mar 15.ABSTRACTPathogenic mycobacteria orchestrate the complex cell populations known as granuloma that is the hallmark of tuberculosis. Foam cells, a lipid-rich cell-type, are considered critical for granuloma formation; however, the causative factor in foam cell formation remains unclear. Atherosclerosis is a chronic inflammatory disease characterized by the abundant accumulation of lipid-laden-macrophage-derived foam cells during which cholesterol 25-hydroxylase (CH25H) is crucial in foam cell formation. Here, we show that M. marinum (...
Source: Atherosclerosis - February 29, 2024 Category: Cardiology Authors: Shuang Zhou Ding Zhang Dan Li Hankun Wang Cairong Ding Jingrui Song Weifeng Huang Xuan Xia Ziwei Zhou Shanshan Han Zhu Jin Bo Yan Jacqueline Gonzales Laura E Via Lu Zhang Decheng Wang Source Type: research
An atorvastatin ‐induced positive anti‐HMGCR immune‐mediated necrotizing myopathy case
Key Clinical MessageStatins can commonly cause myopathy. Most of the time, stopping the culprit drug should solve the problem. However, if the drug has been discontinued but muscle weakness continues to worsen, immune-mediated myopathy should be taken into consideration. (Source: Clinical Case Reports)
Source: Clinical Case Reports - February 29, 2024 Category: General Medicine Authors: Nattanicha Chaisrimaneepan,
Jerapas Thongpiya,
Pitchaporn Yingchoncharoen,
Sakditad Saowapa Tags: CASE REPORT Source Type: research
Zhuyu Pills promote polarization of macrophages toward M2 phenotype to prevent atherosclerosis via PPARgamma/NF-kappaB signaling pathway
In conclusion, Zhuyu Pills may play an anti-atherosclerosis role by regulating PPARγ/NF-κB signaling pathway, inhibiting the polarization of macrophages toward the M1 phenotype, promoting the polarization of macrophages toward the M2 phenotype, and improving the inflammatory microenvironment of macrophages.PMID:38403357 | DOI:10.19540/j.cnki.cjcmm.20230823.501 (Source: Atherosclerosis)
Source: Atherosclerosis - February 25, 2024 Category: Cardiology Authors: Wei Song Zhong-Yi Zhang Kai Wang Hai-Rong Qiu Xiao-Bo Zhang Tao Shen Source Type: research
Environmentally relevant concentrations of aqueous atorvastatin produce alterations in cholesterol biosynthesis and gene expression patterns in Xenopus laevis
Aquat Toxicol. 2024 Feb 5;269:106856. doi: 10.1016/j.aquatox.2024.106856. Online ahead of print.ABSTRACTNumerous studies report active pharmaceutical compounds detected in both wastewater effluent and surface waters. Exposure to statin drugs in general, and atorvastatin in particular, is likely to be a concern. We hypothesized that chronic exposure to low concentrations of atorvastatin in water would result in an adverse effect on production of steroids regulating growth and development of the model amphibian Xenopus laevis. The FETAX assay was used to evaluate the effects of a range of doses of atorvastatin on developing ...
Source: Aquatic Toxicology - February 24, 2024 Category: Toxicology Authors: J R Johnson R J Griffitt Source Type: research
Environmentally relevant concentrations of aqueous atorvastatin produce alterations in cholesterol biosynthesis and gene expression patterns in Xenopus laevis
Aquat Toxicol. 2024 Feb 5;269:106856. doi: 10.1016/j.aquatox.2024.106856. Online ahead of print.ABSTRACTNumerous studies report active pharmaceutical compounds detected in both wastewater effluent and surface waters. Exposure to statin drugs in general, and atorvastatin in particular, is likely to be a concern. We hypothesized that chronic exposure to low concentrations of atorvastatin in water would result in an adverse effect on production of steroids regulating growth and development of the model amphibian Xenopus laevis. The FETAX assay was used to evaluate the effects of a range of doses of atorvastatin on developing ...
Source: Aquatic Toxicology - February 24, 2024 Category: Toxicology Authors: J R Johnson R J Griffitt Source Type: research
Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial
CONCLUSIONS: In adults with severe or critical COVID-19, atorvastatin did not reduce the risk of 28-day or 6-month mortality and did not shorten the length of hospital stay or time to clinical improvement. Trial registration Clinical Trial Registry (NCT04952350) on July 1st, 2021. https://clinicaltrials.gov/ct2/show/NCT04952350.PMID:38389078 | PMC:PMC10885389 | DOI:10.1186/s12931-024-02732-2 (Source: Respiratory Care)
Source: Respiratory Care - February 23, 2024 Category: Respiratory Medicine Authors: Naglaa Hamdi Eltahan Neamat Hamdy Elsawy Kholoud M Abdelaaty Amal Salah Elhamaky Ahmed H Hassan Moataz Maher Emara Source Type: research
Assessment of drug utilization and potentially inappropriate medications in hemodialysis patients with end-stage renal dysfunction: A study in a tertiary care hospital in Bahrain
CONCLUSION: A huge burden of drug therapy was observed in the hemodialysis patients in terms of higher proportions of PIM, complex medical regimen, and prescription of drugs with risk of TdP. Implementation of clinical decision support tools enhancing rational prescription and identification of drugs with TdP risk, introducing antimicrobial stewardship, and stepwise deprescription of the drugs with the least benefit-risk ratio are warranted.PMID:38393922 | DOI:10.3233/JRS-230004 (Source: International Journal of Risk and Safety in Medicine)
Source: International Journal of Risk and Safety in Medicine - February 23, 2024 Category: Drugs & Pharmacology Authors: Kannan Sridharan Source Type: research
Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial
CONCLUSIONS: In adults with severe or critical COVID-19, atorvastatin did not reduce the risk of 28-day or 6-month mortality and did not shorten the length of hospital stay or time to clinical improvement. Trial registration Clinical Trial Registry (NCT04952350) on July 1st, 2021. https://clinicaltrials.gov/ct2/show/NCT04952350.PMID:38389078 | PMC:PMC10885389 | DOI:10.1186/s12931-024-02732-2 (Source: Respiratory Care)
Source: Respiratory Care - February 23, 2024 Category: Respiratory Medicine Authors: Naglaa Hamdi Eltahan Neamat Hamdy Elsawy Kholoud M Abdelaaty Amal Salah Elhamaky Ahmed H Hassan Moataz Maher Emara Source Type: research
Assessment of drug utilization and potentially inappropriate medications in hemodialysis patients with end-stage renal dysfunction: A study in a tertiary care hospital in Bahrain
CONCLUSION: A huge burden of drug therapy was observed in the hemodialysis patients in terms of higher proportions of PIM, complex medical regimen, and prescription of drugs with risk of TdP. Implementation of clinical decision support tools enhancing rational prescription and identification of drugs with TdP risk, introducing antimicrobial stewardship, and stepwise deprescription of the drugs with the least benefit-risk ratio are warranted.PMID:38393922 | DOI:10.3233/JRS-230004 (Source: International Journal of Risk and Safety in Medicine)
Source: International Journal of Risk and Safety in Medicine - February 23, 2024 Category: Drugs & Pharmacology Authors: Kannan Sridharan Source Type: research
